Intae Moon (Tue 10/25 – 7pm poster talk)
A comprehensive analysis of clinical and polygenic germline influences on somatic mutational burden with implications for survival
Kodi Taraszka (Wed 10/26 – 2pm platform)
Germline polygenic risk scores predict cancer patient response and treatment failure
Danielle Kurant (Fri 10/28 – 11:45am platform)
Utilizing Electronic Health Records (EHR) and Tumor Panel Sequencing to Demystify Prognosis of Cancer of Unknown Primary (CUP) patients
Intae Moon (Wed 10/26 – 3pm) [Board No. PB1229]
A new framework for efficient Perturb-seq enables cheap large-scale dissection of the innate immune response and provides insight into regulatory eQTL relationships
Doug Yao (Wed 10/26 – 3pm) [Board No. PB2882]
Allelic imbalance of chromatin accessibility in cancer identifies candidate causal risk variants and their mechanisms
Dennis Grishin (Wed 10/26 – 3pm) [Board No. PB3299]
Germline genetics of venous thromboembolism (VTE): Non-cancer polygenic risk scores improve risk stratification in cancer patients
Stefan Groha (Thu 10/27 – 3pm) [Board No. PB1121]
Germline cancer gene expression quantitative trait loci influence local and global tumor mutations.
Yuxi Liu (Wed 10/26 – 1:45pm platform)
Seeing beyond the target: leveraging off-target reads in targeted clinical tumor sequencing to identify prognostic biomarkers and survival
Yesha Patel (Thu 10/27 – 1:45 platform)
Low-coverage sequencing induces uncertainty in polygenic scoring [Board No. PB3495]
Ella Petter (Wed 10/26 – 3pm poster)